Guardant Health : J.P. Morgan Healthcare Conference Presentation

Transforming cancer care

Presentation

January 2022

Safe Harbor

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "to," "target," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. All statements other than statements of historical fact could be deemed forward-looking, including any expectations regarding the Company's commercial engine as a force multiplier for research and development initiatives; any projections of market opportunities or any statements regarding expectations for future reimbursement opportunities; statements regarding the Company's long-term expectations, including with respect to oncology, liquid biopsy, and other aspects of the Company's industry; statements about launching planned new products and additional laboratories, including with respect to Guardant Reveal, CGP tissue assay, and laboratories outside the United States; statements about the number of patients and clinical sites targeted for, as well as the expected completion of, the Company's ECLIPSE trial; any statements regarding expectations for future regulatory approvals; any statements about historical results that may suggest trends for the Company's business; any statements of the plans, strategies, and objectives of management for future operations and directions; any statements of expectation or belief regarding future events, opportunities to drive future growth, potential markets or market size, or technology developments; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and

2

unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's periodic filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2020, and any current and periodic reports filed thereafter. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company's expectations.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size, penetration and growth and other data about the Company's industry, which involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the Company's future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk.

In light of the foregoing, investors are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company.

Guardant Health is in cancer diagnostics

and delivering a new paradigm of care.

3

Delivering the promise of

				Biopharma
		Regulatory
		Clearance	GuardantOMNI
Medicare				launch
& Private		FDA approval	100+ partners
Coverage
	Guardant 360 CDx
		Launched
NSCLC LCD		3 CDx approvals for	GuardantINFORM
		Targrisso,
Pan-cancer LCD		RYBREVANT &
	LUMAKRAS
& NCD
200M+ covered
lives

4 Guardant Health data on file

				MRD
		International
		Expansion		Launched
				Guardant Reveal
Clinical Volume
Growth		Initiated SCRUM		Initiated ORACLE
		trial in Japan
			COBRA, Pegasus,
250,000+ tests		Acquiring JV		ACT-3
ordered
	Submitted for
11,000+ oncologists		regulatory approval
	in Japan
		Lab partners in UK &
		Spain

Screening

Reached target enrollment for

ECLIPSE

Initiated SHIELD

lung study (enrolled

first patient)

Market-leading

performance in CRC

Strong record of

• 59%

CAGR $360 - 370M

$287M

$214M

$91M

2018

2019

2020

20211

5 1. Guidance issued on November 4, 2021; 2. As of 9/30/2021

Tests ordered

250,000+

Ordering oncologists

11,000+

Biopharma partners

100+

Cash, cash equivalents & marketable securities2

$1.7B